CN110461318A - 用chs-131治疗多发性硬化 - Google Patents

用chs-131治疗多发性硬化 Download PDF

Info

Publication number
CN110461318A
CN110461318A CN201780069826.5A CN201780069826A CN110461318A CN 110461318 A CN110461318 A CN 110461318A CN 201780069826 A CN201780069826 A CN 201780069826A CN 110461318 A CN110461318 A CN 110461318A
Authority
CN
China
Prior art keywords
effective amount
therapeutically effective
compound
multiple sclerosis
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201780069826.5A
Other languages
English (en)
Chinese (zh)
Inventor
B·芬克
R·兹瓦迪诺夫
H·唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellin Therapeutic Co Ltd
Original Assignee
Intellin Therapeutic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellin Therapeutic Co Ltd filed Critical Intellin Therapeutic Co Ltd
Publication of CN110461318A publication Critical patent/CN110461318A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780069826.5A 2016-09-13 2017-09-13 用chs-131治疗多发性硬化 Withdrawn CN110461318A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662394046P 2016-09-13 2016-09-13
US62/394,046 2016-09-13
US201662436356P 2016-12-19 2016-12-19
US62/436,356 2016-12-19
US201762460868P 2017-02-19 2017-02-19
US62/460,868 2017-02-19
US201762491071P 2017-04-27 2017-04-27
US62/491,071 2017-04-27
PCT/US2017/051414 WO2018053040A1 (en) 2016-09-13 2017-09-13 Treatment of multiple sclerosis with chs-131

Publications (1)

Publication Number Publication Date
CN110461318A true CN110461318A (zh) 2019-11-15

Family

ID=61619253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780069826.5A Withdrawn CN110461318A (zh) 2016-09-13 2017-09-13 用chs-131治疗多发性硬化

Country Status (12)

Country Link
US (1) US20190224186A1 (enExample)
EP (1) EP3512512A4 (enExample)
JP (1) JP2019531286A (enExample)
KR (1) KR20190064583A (enExample)
CN (1) CN110461318A (enExample)
AU (1) AU2017326261A1 (enExample)
BR (1) BR112019004791A2 (enExample)
CA (1) CA3036694A1 (enExample)
IL (1) IL265259A (enExample)
MX (1) MX2019002901A (enExample)
SG (1) SG10202102198RA (enExample)
WO (1) WO2018053040A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
EA201992364A1 (ru) * 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228622A (zh) * 2013-01-30 2016-01-06 因特克林医疗有限公司 用于治疗多发性硬化的PPARγ激动剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EA201590726A1 (ru) * 2012-10-12 2015-10-30 Тева Фармасьютикал Индастриз Лтд. Лахинимод для уменьшения таламического поражения при рассеянном склерозе

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228622A (zh) * 2013-01-30 2016-01-06 因特克林医疗有限公司 用于治疗多发性硬化的PPARγ激动剂
JP2016506956A (ja) * 2013-01-30 2016-03-07 インテクリン・セラピユーテイクス・インコーポレイテツド 多発性硬化症を治療するためのＰＰＡＲγアゴニスト

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATRICIA G: "Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis", 《 COHERUS BIOSCIENCES INC 》 *

Also Published As

Publication number Publication date
IL265259A (en) 2019-05-30
EP3512512A1 (en) 2019-07-24
WO2018053040A1 (en) 2018-03-22
BR112019004791A2 (pt) 2019-06-04
CA3036694A1 (en) 2018-03-22
EP3512512A4 (en) 2020-06-03
AU2017326261A1 (en) 2019-04-04
SG10202102198RA (en) 2021-04-29
JP2019531286A (ja) 2019-10-31
MX2019002901A (es) 2019-09-26
US20190224186A1 (en) 2019-07-25
KR20190064583A (ko) 2019-06-10

Similar Documents

Publication Publication Date Title
Arthur et al. The effect of physiological stimuli on sarcopenia; impact of Notch and Wnt signaling on impaired aged skeletal muscle repair
EP3206682B1 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
CN110461318A (zh) 用chs-131治疗多发性硬化
TW201521718A (zh) 低頻率格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之治療
JP6466540B2 (ja) 多発性硬化症を治療するためのＰＰＡＲγアゴニスト
JP2002537332A (ja) 内臓痛を予防及び治療するためのガバペンチン誘導体
JPWO2000009127A1 (ja) 多発性硬化症治療薬
RS64481B1 (sr) Lečenje alchajmerove bolesti kod posebne populacije pacijenata
US20160310481A1 (en) Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders
US12318380B2 (en) Treatment of demyelinating diseases
TW201125562A (en) Sustained release fampridine treatment in patients with multiple sclerosis
WO2014028397A2 (en) Laquinimod for treatment of gaba mediated disorders
EP3160469B1 (en) Methods of managing conditioned fear with neurokinin receptor antagonists
US20210023032A1 (en) Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
JP2022515615A (ja) 慢性炎症性腸疾患の治療のためのｐａｒ－１アンタゴニストの使用
US20190099387A1 (en) Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
Egan et al. HIGHER TROUGH GOLIMUMAB LEVELS ARE ASSOCIATED WITH EARLY CLINICAL AND BIOCHEMICAL RESPONSE; EARLY RESULTS OF THE GOAL-ARC STUDY
Kumar et al. Concurrent nanotherapeutics and regulatory updates for the management of amyotrophic lateral sclerosis: a focused review for orphan drug (Tofersen)
WO2025248089A1 (en) Haloquinolines for treating immune-mediated inflammatory diseases
WO2021050689A1 (en) COMPOSITIONS, METHODS AND USES FOR TARGETING C-TERMINAL BINDING PROTEIN (CtBP) IN TRAUMATIC BRAIN INJURY
JP2022542145A (ja) 神経変性障害の処置のための銅複合体
CN117338938A (zh) 用于治疗中枢神经系统紊乱的组合疗法
HK1221913B (zh) Par-1拮抗剂用於预防和/或治疗骨盆-会阴功能病状的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20191115

WW01 Invention patent application withdrawn after publication